Importantly, HBV-SITE-1 also increased the expression of lots of oncogenic genes such as CDK8, LOXL2, and HIF1A, which have been verified to affect HCC patient prognosis [49, 50]. The gene discussed is LOXL2; the disease is hepatocellular carcinoma.